Clinical Trial Detail

NCT ID NCT03580382
Title Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors New York University School of Medicine
Indications

melanoma

Therapies

CDX-3379 + Trametinib

Age Groups: senior adult

Additional content available in CKB BOOST